Cowen and Company restated their hold rating on shares of Astrazeneca PLC (NYSE:AZN) in a research report sent to investors on Friday. Cowen and Company currently has a $34.00 price objective on the stock.
A number of other equities analysts have also weighed in on AZN. UBS AG lowered Astrazeneca PLC from a buy rating to a neutral rating and dropped their price objective for the stock from $35.44 to $25.55 in a research note on Wednesday, April 5th. HSBC Holdings plc lowered Astrazeneca PLC from a hold rating to a reduce rating in a research note on Friday, April 7th. Jefferies Group LLC reaffirmed a hold rating on shares of Astrazeneca PLC in a research note on Monday, April 10th. Credit Suisse Group raised Astrazeneca PLC from an underperform rating to a neutral rating in a research note on Friday, May 12th. Finally, Leerink Swann reaffirmed an outperform rating and issued a $36.00 price objective (up previously from $33.00) on shares of Astrazeneca PLC in a research note on Wednesday, May 17th. Four investment analysts have rated the stock with a sell rating, ten have given a hold rating and ten have assigned a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus target price of $33.39.
Shares of Astrazeneca PLC (NYSE:AZN) traded up 4.81% on Friday, reaching $30.27. The company’s stock had a trading volume of 13,288,762 shares. Astrazeneca PLC has a 12-month low of $25.55 and a 12-month high of $35.60. The company’s 50-day moving average is $33.80 and its 200 day moving average is $31.30. The company has a market capitalization of $76.64 billion, a price-to-earnings ratio of 19.86 and a beta of 0.77. Astrazeneca PLC also was the recipient of unusually large options trading on Wednesday. Stock traders acquired 8,259 put options on the company. This is an increase of approximately 1,510% compared to the typical volume of 513 put options.
Astrazeneca PLC (NYSE:AZN) last released its quarterly earnings data on Thursday, July 27th. The company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.46. The firm had revenue of $5.05 billion during the quarter, compared to analyst estimates of $5.04 billion. Astrazeneca PLC had a return on equity of 35.88% and a net margin of 17.80%. The business’s quarterly revenue was down 9.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.83 earnings per share. Equities analysts anticipate that Astrazeneca PLC will post $1.85 earnings per share for the current fiscal year.
WARNING: This story was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://stocknewstimes.com/2017/07/29/astrazeneca-plc-nyseazn-stock-rating-reaffirmed-by-cowen-and-company.html.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Salem Investment Counselors Inc. purchased a new position in Astrazeneca PLC during the first quarter valued at approximately $107,000. Meeder Asset Management Inc. purchased a new position in Astrazeneca PLC during the second quarter valued at approximately $105,000. Tompkins Financial Corp increased its position in Astrazeneca PLC by 67.0% in the first quarter. Tompkins Financial Corp now owns 3,545 shares of the company’s stock valued at $100,000 after buying an additional 1,422 shares during the last quarter. Tower Research Capital LLC TRC increased its position in Astrazeneca PLC by 3,782.0% in the first quarter. Tower Research Capital LLC TRC now owns 3,882 shares of the company’s stock valued at $121,000 after buying an additional 3,782 shares during the last quarter. Finally, CENTRAL TRUST Co increased its position in Astrazeneca PLC by 2.1% in the first quarter. CENTRAL TRUST Co now owns 4,499 shares of the company’s stock valued at $140,000 after buying an additional 91 shares during the last quarter. Institutional investors own 14.37% of the company’s stock.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.
